Worth reading
40Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
Applicable field (uses covered by this announcement)
Life and medical care after treatment for patients with esophageal cancer
Launch date26 June 2026 (scheduled, 15:10–16:10)
Relationship between the counterparty and the company
Oncolys BioPharma Inc.4588
Relationship with the Company
Relationship involving the holding of a co-sponsored seminar
CounterpartyAnnual Meeting of the Japanese Esophageal Society / Meeting Secretariat
Location (as indicated in this announcement)
Hotel Hamatsu (3-18 Toramarumachi, Koriyama, Fukushima)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Counterparty | Annual Meeting of the Japanese Esophageal Society / Meeting Secretariat |
| Relationship with the Company | Relationship involving the holding of a co-sponsored seminar |
| Launch date | 26 June 2026 (scheduled, 15:10–16:10) |
| Applicable area | Life and medical care after treatment for patients with esophageal cancer |
| Location | Hotel Hamatsu (3-18 Toramarumachi, Koriyama, Fukushima) |
Items this document does not state (13)
Names of Products / Services CoveredCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To create an opportunity for a broad range of patients with esophageal cancer to share their views.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.